A Q&A with Bruno Hochhegger, MD, PhD & Joice Prodigios, Research Fellow
What do you find most beneficial about being a part of OSIC?
OSIC's collaborative environment for sharing knowledge and resources within the scientific community is invaluable. By working together to improve our understanding of interstitial lung diseases (ILDs), we can help bring patients better clinical outcomes.
What has been the most rewarding aspect of your long-standing membership?
Working with a multidisciplinary team to help achieve better outcomes has been a great reward. We are also very proud of the more than 1,000 anonymized patient cases we’ve been able to contribute to the OSIC Cloud Data Repository. We believe that building reliable and representative databases is the only way to develop the future of artificial intelligence. The addition of these cases can make a huge contribution to future ILD research.
For people wondering if they should join OSIC, what would you say to them? What is the value of being a part of this organization?
OSIC harnesses the power of data to improve clinical patient outcomes. We are looking for nuances and patterns that human eyes are not capturing, but that information could be revealed through the human brain empowered by the artificial intelligence. Some crucial information can be found, and a tremendous impact could be achieved in diagnosis, prognosis and outcomes.
If you had a crystal ball, what do you think OSIC will have accomplished in five years?
Implementation of algorithms in clinical practice that could help in earlier diagnosis of some fibrotic lung diseases that will effectively improve patient’s quality of life. We’re confident that in the coming years, someone will find an image biomarker that will make this possible.